Novel therapies for sepsis: antiendotoxin therapies (Q35011910)

5 August 2017

1 reference

title

Novel therapies for sepsis: antiendotoxin therapies (English)

1 reference

5 August 2017

0 references

Sanjay Manocha

1

1 reference

5 August 2017

Daniel Feinstein

series ordinal

2

1 reference

5 August 2017

Aseem Kumar

series ordinal

3

1 reference

5 August 2017

Anand Kumar

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

1 reference

5 August 2017

11

1 reference

5 August 2017

12

1 reference

5 August 2017

1795-1812

1 reference

Molecular basis of host-pathogen interaction in septic shock

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Structure and function of lipopolysaccharide binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

CD14, new aspects of ligand and signal diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Recognition of gram-negative bacteria and endotoxin by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

HA-1A in septic patients with ARDS: results from the pivotal trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Antibodies against CD14 protect primates from endotoxin-induced shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Immunological therapy of sepsis: experimental therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Bactericidal/permeability-increasing protein--lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats .

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

In vivo protection against endotoxin by plasma high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Endogenous lipoproteins impact the response to endotoxin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Endotoxin tolerance: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

A phase II randomized, controlled trial of continuous hemofiltration in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Endotoxemia in human septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

Bacterial DNA causes septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1795

10.1517/13543784.11.12.1795

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference